Another important excerpt from this:Prof Itescu said the positive response from the FDA also augured well for the company’s development platform as a whole.
The Revascor compound, for use in patients with end-stage ischaemic heart failure, is also looking good. The FDA has allowed the company to file for accelerated approval in a subset of patients at the more serious end of the disease spectrum.
banter and General Discussion, page-10882
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.47 |
Change
0.080(5.78%) |
Mkt cap ! $1.587B | |||
| Open | High | Low | Value | Volume |
| $1.39 | $1.50 | $1.38 | $4.164M | 2.894M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 16014 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 395 | 4 |
View Market Depth
| Last trade - 13.06pm 11/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |